Sort
51,593 grants matching “hepatitis”
Role of Innate and Adaptive Immune Systems in Drug-Induced Liver Disease
$695,282Lance R Pohl · National Heart, Lung, And Blood Institute · ZIA · FY2012 · HL
Chlamydial Vaccine Testing in Mice and Guinea Pigs
$695,230Nilu Goonetilleke · Univ Of North Carolina Chapel Hill · U19 · FY2023 · AI
Discovery of SARS-CoV-2 antivirals using a replicon assay
$695,135Stefan G Sarafianos · Emory University · R01 · FY2025 · AI
Alcohol Research Consortium in HIV: Implementation Research Arm
$695,020Geetanjali Chander · Johns Hopkins University · P01 · FY2021 · AA
Mechanistic Studies of Combination Adjuvants to Target B Cells in Vaccines
$694,960Luc Teyton · Scripps Research Institute, The · U01 · FY2025 · AI
Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women
$694,955Andrea A. Kovacs · University Of Southern California · R01 · FY2019 · DA
Genetic and Metabolic Basis of Familial Lipodystrophies
$694,902Abhimanyu Garg · Ut Southwestern Medical Center · R01 · FY2025 · DK
Genetic and Metabolic Basis of Familial Lipodystrophies
$694,902Abhimanyu Garg · Ut Southwestern Medical Center · R01 · FY2023 · DK
Probing short and long term consequences of Small and Large Bowel Microbiota Transplants on Host Physiology: Implications for the development of future live biotherapeutics
$694,768Eugene B Chang · University Of Chicago · R01 · FY2025 · DK
Community Developed Technology-Based Messaging to Increase SARS-CoV-2 Vaccine Uptake Among People Who Inject Drugs
$694,606Ian David Aronson · New York University · R01 · FY2021 · DA
Upregulation of soluble TNFR2 as treatment for Rheumatiod Arthritis
$694,600Peter Sazani · Avi Biopharma, Inc. · R42 · FY2009 · AR
In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma
$694,475Hamid Ghandehari · Theratarget · R42 · FY2017 · CA
Biomarkers for Peripheral Circadian Clocks in Humans
$694,449Kenneth P Wright · University Of Colorado · R01 · FY2023 · HL
Hepatitis C Pathogenesis and the Human Genome
$694,428David L Thomas · Johns Hopkins University · R01 · FY2012 · DA
Nutrient overload, insulin resistance, and hepatic mitochondrial dysfunction
$694,416Elizabeth Jane Parks · University Of Missouri-Columbia · R01 · FY2018 · DK
Novel Targets for Reducing Atherosclerosis in Type 1 Diabetes
$694,247Sudha B Biddinger · Boston Children'S Hospital · R01 · FY2025 · HL
Colorado Hepatitis C Cooperative Research Center
$694,228Hugo R Rosen · University Of Colorado Denver · U19 · FY2013 · AI
Glycemic and Weight Loss Effects of Semaglutide in Subjects After Spinal Cord Injury and Type 2 Diabetes
$694,221Marzieh Salehi · University Of Texas Hlth Science Center · R01 · FY2025 · DK
Fatty liver disease and its determinants in an American Indian Population: the Strong Heart Study
$694,166Shelley A Cole · Texas Biomedical Research Institute · R01 · FY2017 · DK
Treating secondary cardiomyopathies by mimicking the adaptive hepatic glucose fasting response
$694,067Brian Jesse Debosch · Washington University · R01 · FY2020 · HL
Fluorescence Microscopy
$694,065James W Putney · National Institute Of Environmental Health Sciences · ZIC · FY2014 · ES
Risk Thresholds of Alcohol and Polysubstance Use Among Older Adults
$693,883Katherine Joann Hoggatt · Northern California Institute/Res/Edu · R56 · FY2021 · AG
Towards Evidence-Based Monitoring of Low Dose Methotrexate: CIRT Ancillary Study
$693,860Daniel Hal Solomon · Brigham And Women'S Hospital · R01 · FY2014 · HL
Sickle Cell Disease and Sickle Cell Trait Protection Against HIV-1-infection in Africans and African Americans
$693,795Sergei Nekhai · Howard University · R01 · FY2021 · HL
Impact of HCV Therapy on CNS Outcomes
$693,763Ajay R Bharti · University Of California, San Diego · R01 · FY2017 · DA